CD4 and tuberculosis: This discrepancy may reflect a reluctance of countries to implement rapid (same day) ART initiation for PHW undergoing tuberculosis screening or within 2 weeks for those starting tuberculosis treatment given the increased risk of immune reconstitution inflammatory syndrome and the absence of mortality benefit for patients with CD4 + count > 50 cells/mm3 in randomized controlled trials [23].